Skip to main content
BriaCell Therapeutics Corp. logo

BriaCell Therapeutics Corp. — Investor Relations & Filings

Ticker · BCTX ISIN · CA10778Y3007 LEI · 529900NQNTTXYE874283 US Professional, scientific and technical activities
Open in API
Filings indexed 309 across all filing types
Latest filing 2026-06-02 Share Issue/Capital Cha…
Country CA Canada
Listing US BCTX

About BriaCell Therapeutics Corp.

https://briacell.com/

BriaCell Therapeutics Corp. is a clinical-stage immuno-oncology company developing a novel class of targeted cellular immunotherapies for cancer. Its lead candidate, Bria-IMT™, is a patented, off-the-shelf, cell-based therapy in a pivotal Phase 3 study for advanced metastatic breast cancer. Bria-IMT™, which has received FDA Fast Track designation, is designed to activate the patient's immune system to kill cancer cells. The company is also advancing its next-generation Bria-OTS™ platform, a personalized off-the-shelf immunotherapy that uses HLA matching to provide treatment for a broad patient population. Clinical studies for the Bria-OTS™ platform are ongoing for breast cancer, with planned expansion into prostate cancer, lung cancer, and melanoma.

Recent filings

Filing Released Lang Actions
424B5
Share Issue/Capital Change Classification · 85% confidence The document is a Rule 424(b)(5) prospectus supplement and accompanying base prospectus for an underwritten public offering of 1,449,300 new common shares by BriaCell Therapeutics. It details the terms of a new share issuance, pricing, and distribution arrangements. This is not a general financial report, earnings release, or meeting material, but the formal registering and offering of new equity; it best fits the “Share Issue/Capital Change” category (SHA).
2026-06-02 English
8-K - BRIACELL THERAPEUTICS CORP. (0001610820) (Filer)
Regulatory Filings
2026-02-20 English
DEF 14A Filing
Proxy Solicitation & Information Statement
2026-02-12 English
SCHEDULE 13G Filing
Major Shareholding Notification
2026-01-23 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 15, 2026, by BriaCell Therapeutics Corp. It reports the consummation of a public offering of units and pre-funded units, detailing the terms of the offering, the warrants issued, and the placement agency agreement. The document includes descriptions of securities offered, agreements related to the offering, and press releases announcing the pricing and closing of the offering. There are no financial statements or comprehensive financial data presented, but rather an update on a capital raising event. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length is over 10,000 characters, indicating it is a full report rather than a brief announcement. Therefore, the appropriate classification is CAP with high confidence.
2026-01-15 English
424B4
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus filed pursuant to Rule 424(b)(4) related to a securities offering by BriaCell Therapeutics Corp. It includes information about the offering of common units, pre-funded units, warrants, pricing, use of proceeds, risk factors, and other details typical of a securities offering document. The presence of terms like 'prospectus', 'offering', 'placement agent', 'public offering price', and detailed securities descriptions clearly indicate this is a capital raising document. It is not an annual report, earnings release, management discussion, or any other type of report. It is specifically a registration/prospectus document related to capital raising activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2026-01-14 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.